PSYENCE BIOMEDICAL LTD.
PBMDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next quarter
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Psilocybin therapy | Phase 2 | Adjustment Disorder | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in PSYENCE BIOMEDICAL LTD.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in PSYENCE BIOMEDICAL LTD.'s (PBM) pipeline across Phase 2. Its lead program is Psilocybin therapy (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PSYENCE BIOMEDICAL LTD.'s next FDA catalyst?→
PSYENCE BIOMEDICAL LTD.'s (PBM) next tracked catalyst is a Phase 2 expected December 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PBM biotech catalysts?→
Add PBM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PSYENCE BIOMEDICAL LTD.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.